How is healthcare changing in Europe?

How can we rethink partnerships between the public and the private sector?

How can patients be truly at the centre of EU healthcare policymaking?

These are some of the questions that break the bubble will try to answer,

with the help of patients, policy makers, industry and

healthcare professionals. Above all, this is a place for experts to share visions, passions,

and solutions to the most pressing EU healthcare policy debates. This is Break the Bubble,

an invoking-in-siseive health podcast, available on Spotify and on your favorite listening platform.

In today's episode, our Senior Council, Eduardo Pisani, sits down with Dominica Mishela,

head of global regulatory policy at PPPTA, to talk about shortages and plasma-derived medicinal

products.

Medicine shortages are a multifaceted issue with different root causes and significant implications for people across Europe.

As part of the break the bubble series, evoke incisive health hosted the event getting ahead of medicine shortages the way forward in Europe.

To gather experts' perspectives and proposals that could improve

supply and access to affordable medicines, taking into account regulatory and industrial

policy.

We are pleased to have Dominica Mischella from the Plasma Protein Therapeutics Association,

also known as PPPTA, to add another specific dimension to this

debate, notably how to mitigate shortages of plasma-derived medicinal products and what

suitable measures could be brought forward by the European Union in its proposed revision

of the general pharmaceutical legislation.

Dominica, thank you very much for your time. It's a pleasure to have you with us. Let's kick off

...